On the stock market since 2015, it operates in the world of health and science. It has 3,650 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 37% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 26 buys and 24 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.69 per share each year — regular cash for whoever holds the stock.
This stock swings about 2 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 3 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, CCLDP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CCLDP is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.